Literature DB >> 9294408

Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies.

A Stefani1, F Spadoni, G Bernardi.   

Abstract

Among the several classes of drugs currently studied as neuroprotective agents, glutamate release blockers have been indicated as being rather effective. In particular, lamotrigine and riluzole have shown promise in the treatment of either acutely developing cellular damages (stroke, posttraumatic lesions) or slowly progressing neurodegenerative diseases as amyotrophic lateral sclerosis. These drugs are supposed to interfere with the release of endogenous glutamate in situ, yet the mechanisms underlying this effect are not fully defined. One possibility is that lamotrigine and riluzole act by inhibiting voltage-dependent inward conductances active in the soma and/or in the axon terminal region. Therefore, we have investigated the effects of lamotrigine and riluzole on the voltage-gated sodium and calcium currents of acutely isolated neurons from the adult rat neocortex. In addition, since phenytoin is a well-known blocker of the sodium channel, we have compared lamotrigine and riluzole responses with the peak current inhibition produced by phenytoin in the same cells. Lamotrigine produced a large reduction of the high-voltage-activated calcium currents and a smaller; use-dependent inhibition of the sodium conductance. Riluzole inhibited significantly the sodium current at surprisingly low concentrations (nanomolar range) and by up to 80% at saturating doses (1-10 microM). Furthermore, riluzole inhibited both high- and low-voltage-activated calcium currents in neocortical neurons isolated from adult and young animals. By contrast, phenytoin caused only a slight reduction of high-voltage-activated calcium currents even at supratherapeutic doses (by < 12% at 10 microM). Taken together, the different pharmacological profiles of the tested agents might indicate that glutamate release blockers do not represent a homogenous class of drugs. Conversely, our findings could support their selective utilization in different disease status.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294408     DOI: 10.1006/exnr.1997.6554

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  31 in total

1.  A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence.

Authors:  E Sherwood Brown; Prabha Sunderajan; Lisa T Hu; Sharon M Sowell; Thomas J Carmody
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

2.  Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder.

Authors:  Vladimir Coric; Snezana Milanovic; Suzanne Wasylink; Pinal Patel; Robert Malison; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-03-26       Impact factor: 4.530

Review 3.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  A novel path to chronic proprioceptive disability with oxaliplatin: Distortion of sensory encoding.

Authors:  Jacob A Vincent; Krystyna B Wieczerzak; Hanna M Gabriel; Paul Nardelli; Mark M Rich; Timothy C Cope
Journal:  Neurobiol Dis       Date:  2016-07-07       Impact factor: 5.996

5.  Functional identification of activity-regulated, high-affinity glutamine transport in hippocampal neurons inhibited by riluzole.

Authors:  Jeffrey D Erickson
Journal:  J Neurochem       Date:  2017-05-18       Impact factor: 5.372

6.  Riluzole is a promising pharmacological inhibitor of bilirubin-induced excitotoxicity in the ventral cochlear nucleus.

Authors:  Guo-Ying Han; Chun-Yan Li; Hai-Bo Shi; Ji-Ping Wang; Kai-Ming Su; Xin-Lu Yin; Shan-Kai Yin
Journal:  CNS Neurosci Ther       Date:  2014-12-12       Impact factor: 5.243

7.  Dopamine D2 receptor desensitization by dopamine or corticotropin releasing factor in ventral tegmental area neurons is associated with increased glutamate release.

Authors:  Sudarat Nimitvilai; Melissa Herman; Chang You; Devinder S Arora; Maureen A McElvain; Marisa Roberto; Mark S Brodie
Journal:  Neuropharmacology       Date:  2014-03-19       Impact factor: 5.250

Review 8.  Brain imaging in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster; Joseph O'Neill; David R Rosenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-11       Impact factor: 8.829

Review 9.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study.

Authors:  S Arpin; E Lagrue; S Bodard; S Chalon; P Castelnau
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.